Side-by-side comparison
AbbVie vs Eli Lilly and
As of Sep 25, 2026, P/E is 74.7x for AbbVie vs 39.7x for Eli Lilly and; P/S is 7.3x for AbbVie vs 14.0x for Eli Lilly and; revenue growth is 10.4% for AbbVie vs 49.6% for Eli Lilly and; net margin is 9.8% for AbbVie vs 33.5% for Eli Lilly and.
Key metrics
| Metric | ABBV | LLY |
|---|---|---|
| Price | $264.34 | $1,183.46 |
| Market cap | $467.12B | $1.11T |
| P/E | 74.7x (#2) | 39.7x (#1) |
| P/S | 7.3x (#1) | 14.0x (#2) |
| Revenue growth | 10.4% (#2) | 49.6% (#1) |
| Operating margin | 26.2% (#1) | — |
| Net margin | 9.8% (#2) | 33.5% (#1) |
| Debt / equity | — | 1.41 (#1) |
| 1-year return | +19.8% (#2) | +63.3% (#1) |
| Research score | 55/100 (#2) | 69/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- AbbVie Inc. (ABBV) — Drug Manufacturers—General
- Eli Lilly and Company (LLY) — Drug Manufacturers—General